SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11206-11216
DOI: 10.1111/dom.71324 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 08.09.2026. Verfasst von Leandra Serio und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Fabry Disease, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD.
Methods
We conducted a retrospective cohort study using the TriNetX Global Collaborative Network, including adults with Fabry disease and eGFR ≥ 20 mL/min/1.73 m 2 , excluding Type 1 diabetes. Patients were stratified by SGLT2 inhibitor exposure. The primary outcome was a composite of all‐cause death, acute myocardial infarction and acute or acute‐on‐chronic heart failure at 2 and 5 years; secondary outcomes included individual components and progression to advanced kidney disease. Patients with prior non‐fatal outcomes were excluded from the respective analyses. Propensity score matching (1:1) and Cox proportional hazards models were used. Sensitivity analyses included alternative follow‐up periods, restriction to Fabry disease diagnosed from 2013 onwards and a stricter Fabry disease definition requiring ≥ 2 diagnoses; subgroup analyses were performed by sex and age.
Results
Among 14 940 FD patients, 1028 (6.9%) had recorded exposure to SGLT2 inhibitors (mean age: 65.5 ± 12.0 years; 53.0% male), who were older and had a higher comorbidity burden and worse baseline renal profile than non‐exposed patients. After PSM, 732 patients per group (exposed and non‐exposed patients) were available for analysis. At 2 years, SGLT2i exposure was associated with a lower risk of the composite outcome (HR 0.61; 95% CI 0.38–0.97) and all‐cause death (HR 0.56; 95% CI 0.33–0.95). At 5 years, results were consistent for the composite outcome (HR 0.56; 95% CI 0.39–0.79) and all‐cause death (HR 0.62; 95% CI 0.42–0.93), with reduced myocardial infarction risk (HR 0.53; 95% CI 0.30–0.90).
Conclusions
In a large real‐world FD cohort, SGLT2i exposure was associated with lower cardiovascular risk and mortality, supporting further prospective investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
- Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
- Internal Medicine and Nephrology Division, ASL1 Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, L'Aquila, Italy.
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
- Internal, Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.
ORCID-Profile: Leandra Serio, Tommaso Bucci, Gregory Y H Lip
Zitieren
APA
Serio, L., Rossi, M., Askarinejad, A., Tartaglia, E., Bucci, T., Marrone, E., Kalra, D. K., Ferri, C., & Lip, G. Y. H. (2026). SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network. Diabetes, Obesity and Metabolism, 28(12), 11206-11216. https://doi.org/10.1111/dom.71324
Vancouver
Serio L, Rossi M, Askarinejad A, Tartaglia E, Bucci T, Marrone E, et al. SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network. Diabetes, Obesity and Metabolism. 2026;28(12):11206-11216. doi:10.1111/dom.71324
BibTeX
@article{Serio2026,
author = {Serio, Leandra and Rossi, Michele and Askarinejad, Amir and Tartaglia, Enrico and Bucci, Tommaso and Marrone, Enrica and Kalra, Dinesh K and Ferri, Claudio and Lip, Gregory Y H},
title = {SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11206--11216},
doi = {10.1111/dom.71324}
}
EUVIMED